Advertisement Sygnis Pharma licenses new amplification buffer to QIAGEN - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sygnis Pharma licenses new amplification buffer to QIAGEN

Spanish-German biotech company Sygnis Pharma has entered into a licence agreement for the distribution of a new amplification buffer with QIAGEN, a sample and assay technologies provider.

This is the second agreement with QIAGEN within nine months; the first licence agreement was signed for the amplification buffer technology developed by the team led by renowned Professor Margarita Salas at the CSIC laboratory.

The recently granted license agreement includes a tool used in isothermal amplification, providing good reaction performance.

Sygnis CEO Pilar de la Huerta said, "This newly signed agreement shows that SYGNIS is making progress in the commercialization of core technologies and products designed for the DNA sequencing and amplification market."